Qatar Charity receives GCC Housing Award
Tribune News Network
Doha
Qatar Charity (QC) has been honoured with the prestigious Gulf Cooperation Council (GCC) Housing Award for the 2024–2025 cycle, during the 23rd GCC Housing Ministers Meeting held in Kuwait.
The award was received by Chief Executive Officer of Qatar Charity, Yousuf bin Ahmed Al-Kuwari, from Kuwait's Minister of State for Municipal and Housing Affairs, Abdul Latif Abdullah Al-Mashari. The ceremony was also attended by Qatar's Minister of Social Development and Family H.E. Buthaina bint Ali Al Jabr Al Nuaimi.
Qatar Charity has implemented several initiatives to support low-income families, widows, and divorcees within Qatar by addressing their housing needs. These efforts include covering rental costs and implementing the 'Renovation' project, which focuses on repairing old homes for low-income families and providing them with suitable furniture.
Chief Executive Officer of Qatar Charity, Yousuf bin Ahmed Al-Kuwari, said, 'We are pleased with this honour, which reflects Qatar Charity's dedication to social housing as part of its contribution to realising Qatar National Vision 2030.
Through initiatives that aim to foster community stability, enhance living standards, and provide healthy housing environments for low-income families and groups, we are committed to making a meaningful impact.' He noted that this recognition will motivate Qatar Charity to pay more attention to such community initiatives.
It is worth mention that the 6th edition of the GCC Housing Award 2024-2025 was held under the theme 'Digital/Smart Applications and Technologies in Housing Projects and Programs.' Cash prizes were awarded to the top three winners, and several organizations were honoured during the official ceremony, including Qatar Charity, which was recognized in the category of private sector and charitable organizations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
2 hours ago
- Qatar Tribune
Sheikha Moza opens HSCT ward at Sidra Medicine
Tribune News Network Doha HH Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development, officially inaugurated the new paediatric Hematopoietic Stem Cell Transplant (HSCT) ward at Sidra Medicine, a Qatar Foundation entity. The new ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions. During the visit, Sheikha Mozatoured the facility, engaged with clinical teams, and received an overview of the HSCT programme's role in advancing care and stem cell and gene therapies for children in Qatar and the region. Sheikha Moza was accompanied by Minister of Public Health HE Mansoor bin Ebrahim bin Saad Al Mahmoud, members of Sidra Medicine's Board of Directors and senior leadership, including Dr Iyabo Tinubu-Karch, Chief Executive Officer and Prof Ibrahim Janahi, Chief Medical Officer. The HSCT ward is a core part of Sidra Medicine's HSCT Programme, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new pediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections - one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
Qatar Tribune
2 hours ago
- Qatar Tribune
‘New paediatric Hematopoietic Stem Cell Transplant Ward expands access to life-saving care for children'
Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new paediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections—one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine, said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
Qatar Tribune
2 hours ago
- Qatar Tribune
Qatar tops Int'l Association of Public Transport MENA ranking
Tribune News Network Doha Qatar ranks first in the Middle East and North Africa (MENA) region in terms of the 'Share of Populations with Convenient Access to Public Transport', with 91.7 percent, according to the International Association of Public Transport (UITP)'s 'MENA Transport Report 2025' issued by the Centre for Transport Excellence. This year's edition broadened its scope, covering public transportation systems in 40 cities across 14 MENA countries. The capital city Doha has the world's highest number of kilometres per million inhabitants (64km/1 million population) compared to several world capital cities. Doha also ranks third globally in terms of number of public buses for every one million inhabitants (969 buses/1 million inhabitants), which reflects Qatar's significant investment in public transportation. Regarding the metro network fleet, Doha comes fourth globally in terms of number of metro cars (278 cars/1 million inhabitants). The UITP report lists Qatar among the top 20 countries in the world in terms of public transportation user experience alongside Amsterdam, Geneva and Singapore. The report shows Qatar as one of the most efficient countries in terms of public transportation fare according to the Purchasing Power Parity (PPP), making public transportation affordable for all. According to the report, Qatar has one of the highest rankings in the MENA region in environmental sustainability of the transportation system with comprehensive plans for transition to clean energy. It also highlights Qatar among top countries in terms of the smart infrastructure for the public transportation system. The report lauds Qatar's qualitative progress in upgrading its public transportation system in terms of infrastructure, sustainability, digital transformation, and integration of mobility modes, thereby meeting the needs of its population and visitors and supporting the Qatar National Vision 2030. The report also highlighted the Doha Metro as one of the most advanced and most efficient mobility systems in the world thanks to its full driverless automation and high ridership per every 1 million people. It also lauded Doha Metro's role in the success of major events Qatar organizes or hosts, first and foremost the FIFA World Cup Qatar 2022 where fans enjoyed safe and smooth movement. The report says Lusail Tram stands out and reflects ambitious urban planning. Serving the smart city of Lusail with the highest rates of kilometers per each one million inhabitants if compared to similar cities, the report said Lusail tramway network reflects a forward-looking vision to enhance urban mobility. The report says: 'Qatar has taken significant steps toward electrification, with Doha integrating electric buses into its public transport network. Qatar has outlined plans to transition its public bus fleet to full electrification by 2030, supported by an expanding charging infrastructure and investments in smart mobility.' The report adds that Lusail is home to the world's largest e-bus depot running on solar energy to feed its facilities, with advanced infrastructures including smart charging stations, digital tracking systems, and green maintenance centres. The report also praised Qatar's success in integrating various transportation modes into one system while making several solutions available for users such as electronic payment using cards and via applications and smart platforms for trip planning and bus tracking, something which helps achieve smooth and efficient connectivity between metro networks, buses, trams and shared mobility.
